|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Current assets: | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Restricted cash | ||||||||||||||||
| Accounts receivable, net of allowances | ||||||||||||||||
| Income tax receivable | ||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||
| Total current assets | ||||||||||||||||
| Property and equipment, net | ||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||
| Goodwill | ||||||||||||||||
| Intangible assets, net | ||||||||||||||||
| Other long-term assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Current portion of long-term debt | ||||||||||||||||
| Current operating lease liabilities | ||||||||||||||||
| Accounts payable | ||||||||||||||||
| Accrued payroll | ||||||||||||||||
| Refunds due patients and other third-party payers | ||||||||||||||||
| Accrued medical insurance | ||||||||||||||||
| Other current liabilities | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| Long-term debt, net of current portion | ||||||||||||||||
| Long-term operating lease liabilities, net of current portion | ||||||||||||||||
| Deferred income tax liabilities | ||||||||||||||||
| Other long-term liabilities | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||
| Preferred stock, $0.10 par value; 1,500,000 shares authorized; no shares issued | ||||||||||||||||
| Common stock, $0.01 par value; 200,000,000 shares authorized; 51,195,035 and 50,589,768 shares issued; and 50,723,245 and 50,369,917 shares outstanding as of December 31, 2025 and 2024, respectively | ||||||||||||||||
| Capital in excess of par value | ||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||
| Retained earnings | ||||||||||||||||
| Treasury stock, at cost, 471,790 and $219,851 shares as of December 31, 2025 and 2024, respectively | ||||||||||||||||
| Total Enhabit, Inc. stockholders’ equity | ||||||||||||||||
| Noncontrolling interests | ||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||
| Treasury stock (in shares) | ||||||||||||||||
Loading...
